fastGEN MPN Cancer Kit
We are introducing a new addition to the fastGEN portfolio – the fastGEN MPN Cancer Kit, designed for the molecular diagnostics of myeloproliferative neoplasms (MPN).
Quote-based, no public pricing. Add to your quote and our specialists put together a proposal with the right documentation, typically within 24 hours.
This kit in detail
Description
Myeloproliferative neoplasms are a group of hematological disorders characterized by increased proliferation of blood cells in the bone marrow. The main subtypes include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The pathogenesis of these diseases is closely associated with activating somatic mutations in the JAK2, MPL, and CALR genes, leading to constitutive activation of the JAK–STAT signaling pathway.
Molecular diagnostics of these mutations, according to WHO classification, is essential for accurate diagnosis, disease monitoring, and selection of targeted therapy – knowledge of the mutational profile is a cornerstone of personalized medicine.
Compatibility
Compatible with all Illumina platforms, for other platforms use conversion kit.
Bioinformatic analysis software: GENOVESA
The GENOVESA fastGEN software module, available online, can be used to analyse sequencing data. It is an all-in-one cloud solution for raw data analysis (FASTQ files), with technical and application support.
Specifications
- Product: fastGEN MPN Cancer Kit
- Cat. No.: RDNGS0021 — 16 samples (1 kit)
- Regulatory status: RUO
- Type: fastGEN
- Species: Human
- Other names: JAK2, CALR, MPL
- Research topic: Oncology
- Applications: Isolated DNA
Datasheets and regulatory documentation
Everything your quality team needs for evaluation and procurement.
Example Instructions for Use (RUO)
Safety Information (RUO)
Supporting Documents — Run Assignment
Supporting Documents — Application documents
Product Brochure
Add this kit to your quote
Tell us the platforms and throughput you’re planning for and our specialists will put together a clear proposal with the right documentation, no public pricing, just a considered answer.
